基质金属蛋白酶
药物输送
类风湿性关节炎
炎症
医学
细胞因子
药品
药理学
心肌梗塞
免疫学
内科学
材料科学
纳米技术
作者
Björn ter Mors,Valerie Spieler,Eduardo Merino Asumendi,Benedikt Gantert,Tessa Lühmann,Lorenz Meinel
出处
期刊:ACS Biomaterials Science & Engineering
[American Chemical Society]
日期:2023-04-27
标识
DOI:10.1021/acsbiomaterials.2c01320
摘要
Cytokines are regulated in acute and chronic inflammation, including rheumatoid arthritis (RA) and myocardial infarction (MI). However, the dynamic windows within which cytokine activity/inhibition is desirable in RA and MI change timely and locally during the disease. Therefore, traditional, static delivery regimens are unlikely to meet the idiosyncrasy of these highly dynamic pathophysiological and individual processes. Responsive delivery systems and biomaterials, sensing surrogate markers of inflammation (i.e., matrix metalloproteinases - MMPs) and answering with drug release, may present drug activity at the right time, manner, and place. This article discusses MMPs as surrogate markers for disease activity in RA and MI to clock drug discharge to MMP concentration profiles from MMP-responsive drug delivery systems and biomaterials.
科研通智能强力驱动
Strongly Powered by AbleSci AI